www.urologiepropraxi.cz / Urol. praxi. 2024;25(1):32-37 / UROLOGIE PRO PRAXI 37 Z POMEZÍ UROLOGIE Management nežádoucích účinků léčby karcinomu ledviny ků a zejména pak irAEs měla věnovat větší pozornost již v rámci plánování prospektivních klinických studií. I vzhledem k výše zmíněnému předpokladu, že trend kombinování léčiv k dosažení vyšší efektivity protinádorové léčby bude pokračovat, což může vést ke zvýšenému výskytu i vyšší závažnosti nežádoucích účinků terapie, je totiž jednoznačně zapotřebí identifikovat nové genetické a mikrobiální biomarkery nejen imunitně podmíněných nežádoucích účinků a aktivně rozvíjet možnosti jejich předcházení (25). LITERATURA 1. Motzer RJ, Hutson TE, Tomczak P, et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 2009;27(22):3584-3590. 2. Alonso-Gordoa T, García-Bermejo ML, Grande E, et al. Targeting Tyrosine kinases in Renal Cell Carcinoma: „New Bullets against Old Guys”. International Journal of Molecular Sciences. 2019;20(8):1901. 3. Heng DYC, Xie W, Regan MM, et al. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor – Targeted Agents: Results From a Large, Multicenter Study. Journal of Clinical Oncology. 2009;27(34):5794-5799. 4. Haanen JBAG, Larkin J, Choueiri TK, et al. Extended followup from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open. 2023;8(3):101210. 5. SÚKL, Detail varianty léčivého přípravku (YERVOY – 5MG/ ML INF CNC SOL 1X10ML) [Internet] [Available from: https:// prehledy.sukl.cz/prehled_leciv.html#/leciva/0185101. 6. Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. The Lancet Oncology. 2023;24(3):228-238. 7. Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;402(10397):185-195. 8. Hallare J, Gerriets V. Half Life. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023. 9. EMA, Sutent, Inlyta, Votrient, Cabometyx, Kisplyx : EPAR – Product information [Internet] [Available from: https://www. ema.europa.eu/en/medicines/human. 10. EMA, Afinitor : EPAR – Product information [Internet] Available from: https://www.ema.europa.eu/en/medicines/ human/EPAR/afinitor#product-information-section. 11. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer. 2010;116(18):4256-4265. 12. NCCN Guidelines, Kidney Cancer, Version: 1.2024, [Internet]. 13. Dutcher JP, Flippot R, Fallah J, Escudier B. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment – Cytokines, Targeted Therapy, and Immunotherapy. American Society of Clinical Oncology Educational Book. 2020(40):418-435. 14. Kyllarová A, Kubeček O, Trojanová P, et al. Immunotherapy related toxicities. Onkologie. 2017;11:83-87. 15. Lakomý R, Poprach A. Sideeffects of Modern Immunotherapy and How to Solve Them in the Clinics. Klin Onkol. 2015;28 Suppl 4:4s103-114. 16. Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126(18):4156-4167. 17. Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2022;23(9):1133-1144. 18. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. 19. Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. The Lancet Oncology. 2020;21(12):1563-1573. 20. Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. The Lancet Oncology. 2022;23(7):888-898. 21. Grünwald V, Voss MH, Rini BI, et al. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. British journal of cancer. 2020;123(6):898-904. 22. Choueiri TK, Powles T, Albiges L, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. New England Journal of Medicine. 2023;388(19):1767-1778. 23. Choueiri TK, Plimack ER, Powles T, et al. Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 2022;40(6_ suppl):TPS399-TPS. 24. Choueiri TK, Mcdermott DF, Merchan J, et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. The Lancet Oncology. 2023;24(5):553-562. 25. Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nature Communications. 2022;13(1). 5.–6. 4. 2024 / OLOMOUC / Central Park Flora 35. VÝROČNÍ SETKÁNÍ DĚTSKÝCH UROLOGŮ Bližší informace na: https://uro.registrace-solen.cz
RkJQdWJsaXNoZXIy NDA4Mjc=